Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Lawrence Mayer

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Concepts & Ideas

Physiology

Multiple Drug Resistance

Procedures

Disorders

Neoplasms

Anatomy

Cultured Tumor Cells

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
47
Bally, Marcel
20
Cullis, Pieter
10
Tardi, Paul
9
Masin, Dana
9
Harasym, Troy
9
Webb, Murray
7
Johnstone, Sharon
7
Shabbits, Jennifer
6
Madden, Thomas
6
Hudon, Norma
6
Gelmon, Karen
6
Chiu, Gigi
6
Edwards, Katarina
6
Waterhouse, Dawn
5
Abraham, Sheela

Sign-in to see all Coauthors

Publications

TOP 3
Tardi Paul G; Dos Santos Nancy; Harasym Troy O; Johnstone Sharon A; Zisman Natalia; Tsang Alan W; Bermudes David G; Mayer Lawrence D
Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo.
Dicko Awa; Frazier April A; Liboiron Barry D; Hinderliter Anne; Ellena Jeff F; Xie Xiaowei; Cho Connie; Weber Tom; Tardi Paul G; Cabral-Lilly Donna; Cafiso David S; Mayer Lawrence D
Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes.
Ansell Steven M; Johnstone Sharon A; Tardi Paul G; Lo Lily; Xie Sherwin; Shu Yu; Harasym Troy O; Harasym Natashia L; Williams Laura; Bermudes David; Liboiron Barry D; Saad Walid; Prud'homme Robert K; Mayer Lawrence D
Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Lawrence Mayer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Tardi Paul G; Dos Santos Nancy; Harasym Troy O; Johnstone Sharon A; Zisman Natalia; Tsang Alan W; Bermudes David G; Mayer Lawrence D
Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo.
Molecular cancer therapeutics 2009;8(8):2266-75.
2008: Dicko Awa; Frazier April A; Liboiron Barry D; Hinderliter Anne; Ellena Jeff F; Xie Xiaowei; Cho Connie; Weber Tom; Tardi Paul G; Cabral-Lilly Donna; Cafiso David S; Mayer Lawrence D
Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes.
Pharmaceutical research 2008;25(7):1702-13.
2008: Ansell Steven M; Johnstone Sharon A; Tardi Paul G; Lo Lily; Xie Sherwin; Shu Yu; Harasym Troy O; Harasym Natashia L; Williams Laura; Bermudes David; Liboiron Barry D; Saad Walid; Prud'homme Robert K; Mayer Lawrence D
Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates.
Journal of medicinal chemistry 2008;51(11):3288-96.
2007: Mayer Lawrence D; Janoff Andrew S
Optimizing combination chemotherapy by controlling drug ratios.
Molecular interventions 2007;7(4):216-23.
2007: Tardi Paul G; Gallagher Ryan C; Johnstone Sharon; Harasym Natashia; Webb Murray; Bally Marcel B; Mayer Lawrence D
Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.
Biochimica et biophysica acta 2007;1768(3):678-87.
2007: Webb Murray S; Johnstone Sharon; Morris Tara J; Kennedy Allison; Gallagher Ryan; Harasym Natashia; Harasym Troy; Shew Clifford R; Tardi Paul; Dragowska Wieslawa H; Mayer Lawrence D; Bally Marcel B
In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 2007;65(3):289-99.
2007: Harasym Troy O; Tardi Paul G; Harasym Natashia L; Harvie Pierrot; Johnstone Sharon A; Mayer Lawrence D
Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.
Oncology research 2007;16(8):361-74.
2006: Mayer Lawrence D; Harasym Troy O; Tardi Paul G; Harasym Natashia L; Shew Clifford R; Johnstone Sharon A; Ramsay Euan C; Bally Marcel B; Janoff Andrew S
Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.
Molecular cancer therapeutics 2006;5(7):1854-63.
2006: Ickenstein Ludger M; Sandström Maria C; Mayer Lawrence D; Edwards Katarina
Effects of phospholipid hydrolysis on the aggregate structure in DPPC/DSPE-PEG2000 liposome preparations after gel to liquid crystalline phase transition.
Biochimica et biophysica acta 2006;1758(2):171-80.
2005: Sandström Maria C; Ickenstein Ludger M; Mayer Lawrence D; Edwards Katarina
Effects of lipid segregation and lysolipid dissociation on drug release from thermosensitive liposomes.
Journal of controlled release : official journal of the Controlled Release Society 2005;107(1):131-42.
2005: Guns Emma S; Xie Xiaowei; Fedoruk Matthew; Madera Candice; Cowell Simon; Mayer Lawrence D; Skov Kirsten; Gleave Martin E; Kozlowski Piotr
pH modulation using CsCl enhances therapeutic effects of vitamin D in LNCaP tumor bearing mice.
The Prostate 2005;64(3):316-22.
2005: Abraham Sheela A; Waterhouse Dawn N; Mayer Lawrence D; Cullis Pieter R; Madden Thomas D; Bally Marcel B
The liposomal formulation of doxorubicin.
Methods in enzymology 2005;391():71-97.
2005: Waterhouse Dawn N; Madden Thomas D; Cullis Pieter R; Bally Marcel B; Mayer Lawrence D; Webb Murray S
Preparation, characterization, and biological analysis of liposomal formulations of vincristine.
Methods in enzymology 2005;391():40-57.
2004: Hu YanPing; Bebb Gwyn; Tan Sophia; Ng Rebecca; Yan Hong; Sartor Jason R; Mayer Lawrence D; Bally Marcel B
Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(22):7662-70.
2004: Messerer Corrie Lynn; Ramsay Euan C; Waterhouse Dawn; Ng Rebecca; Simms Eva-Maria; Harasym Natashia; Tardi Paul; Mayer Lawrence D; Bally Marcel B
Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6638-49.
2004: Abraham Sheela A; Edwards Katarina; Karlsson Göran; Hudon Norma; Mayer Lawrence D; Bally Marcel B
An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes.
Journal of controlled release : official journal of the Controlled Release Society 2004;96(3):449-61.
2004: Fedoruk Matthew N; Giménez-Bonafé Pepita; Guns Emma S; Mayer Lawrence D; Nelson Colleen C
P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells.
The Prostate 2004;59(1):77-90.
2004: Dos Santos Nancy; Cox Kelly A; McKenzie Cheryl A; van Baarda Floris; Gallagher Ryan C; Karlsson Goran; Edwards Katarina; Mayer Lawrence D; Allen Christine; Bally Marcel B
pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol.
Biochimica et biophysica acta 2004;1661(1):47-60.
2004: Hu YanPing; Krishan Awtar; Nie WeiJia; Sridhar Kasi S; Mayer Lawrence D; Bally Marcel
Synergistic cytotoxicity of pyrazoloacridine with doxorubicin, etoposide, and topotecan in drug-resistant tumor cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(3):1160-9.
2004: Waterhouse Dawn N; Dragowska Wieslawa H; Gelmon Karen A; Mayer Lawrence D; Bally Marcel B
Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model.
Cancer biology & therapy 2004;3(2):197-204.
2004: Abraham Sheela A; McKenzie Cheryl; Masin Dana; Ng Rebecca; Harasym Troy O; Mayer Lawrence D; Bally Marcel B
In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(2):728-38.
2003: Shabbits Jennifer A; Mayer Lawrence D
High ceramide content liposomes with in vivo antitumor activity.
Anticancer research 2003;23(5A):3663-9.
2003: Shabbits Jennifer A; Hu Yanping; Mayer Lawrence D
Tumor chemosensitization strategies based on apoptosis manipulations.
Molecular cancer therapeutics 2003;2(8):805-13.
2003: Ickenstein Ludger M; Arfvidsson Maria C; Needham David; Mayer Lawrence D; Edwards Katarina
Disc formation in cholesterol-free liposomes during phase transition.
Biochimica et biophysica acta 2003;1614(2):135-8.
2003: Hu YanPing; Cherton-Horvat Gabriele; Dragowska Visia; Baird Stephen; Korneluk Robert G; Durkin Jon P; Mayer Lawrence D; LaCasse Eric C
Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2826-36.
2003: Chiu Gigi N C; Bally Marcel B; Mayer Lawrence D
Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis.
Biochimica et biophysica acta 2003;1613(1-2):115-21.
2003: Shabbits Jennifer A; Mayer Lawrence D
Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro.
Biochimica et biophysica acta 2003;1612(1):98-106.
2003: Fung Vincent W H; Chiu Gigi N C; Mayer Lawrence D
Application of purging biotinylated liposomes from plasma to elucidate influx and efflux processes associated with accumulation of liposomes in solid tumors.
Biochimica et biophysica acta 2003;1611(1-2):63-9.
2003: Lopes de Menezes Daniel E; Hu Yanping; Mayer Lawrence D
Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice.
Journal of experimental therapeutics & oncology 2003;3(2):72-82.
2002: Shabbits Jennifer A; Chiu Gigi N C; Mayer Lawrence D
Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems.
Journal of controlled release : official journal of the Controlled Release Society 2002;84(3):161-70.
2002: Abraham Sheela Ann; Edwards Katarina; Karlsson Göran; MacIntosh Scott; Mayer Lawrence D; McKenzie Cheryl; Bally Marcel B
Formation of transition metal-doxorubicin complexes inside liposomes.
Biochimica et biophysica acta 2002;1565(1):41-54.
2002: Allen C; Dos Santos N; Gallagher R; Chiu G N C; Shu Y; Li W M; Johnstone S A; Janoff A S; Mayer L D; Webb M S; Bally M B
Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol).
Bioscience reports 2002;22(2):225-50.
2002: Dos Santos Nancy; Mayer Lawrence D; Abraham Sheela A; Gallagher Ryan C; Cox Kelly A K; Tardi Paul G; Bally Marcel B
Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes.
Biochimica et biophysica acta 2002;1561(2):188-201.
2002: Mayer Lawrence D; Lim Kye-Taek; Hartley Daria
Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P-glycoprotein.
Journal of experimental therapeutics & oncology 2002;2(2):107-20.
2002: Li Wai Ming; Mayer Lawrence D; Bally Marcel B
Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids.
The Journal of pharmacology and experimental therapeutics 2002;300(3):976-83.
2002: Chiu Gigi N C; Bally Marcel B; Mayer Lawrence D
Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids.
Biochimica et biophysica acta 2002;1560(1-2):37-50.
2002: Denyssevych T; Lestou V S; Knesevich S; Robichaud M; Salski C; Tan R; Gascoyne R D; Horsman D E; Mayer L D
Establishment and comprehensive analysis of a new human transformed follicular lymphoma B cell line, Tat-1.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(2):276-83.
2002: Shabbits Jennifer A; Mayer Lawrence D
P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs.
Molecular cancer therapeutics 2002;1(3):205-13.
2002: Lopes de Menezes Daniel E; Mayer Lawrence D
Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
Cancer chemotherapy and pharmacology 2002;49(1):57-68.
2001: Shabbits J A; Krishna R; Mayer L D
Molecular and pharmacological strategies to overcome multidrug resistance.
Expert review of anticancer therapy 2001;1(4):585-94.
2001: Guns E S; Bullock P L; Reimer M L; Dixon R; Bally M; Mayer L D
Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes.
European journal of drug metabolism and pharmacokinetics 2001;26(4):273-82.
2001: Waterhouse D N; Dos Santos N; Mayer L D; Bally M B
Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs.
Pharmaceutical research 2001;18(9):1331-5.
2001: Krishna R; Webb M S; St Onge G; Mayer L D
Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties.
The Journal of pharmacology and experimental therapeutics 2001;298(3):1206-12.
2001: Li W M; Xue L; Mayer L D; Bally M B
Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes.
Biochimica et biophysica acta 2001;1513(2):193-206.
2001: Chiu G N; Bally M B; Mayer L D
Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol).
Biochimica et biophysica acta 2001;1510(1-2):56-69.
2001: Mayer L D; Shabbits J A
The role for liposomal drug delivery in molecular and pharmacological strategies to overcome multidrug resistance.
Cancer metastasis reviews 2001;20(1-2):87-93.
2001: Waterhouse D N; Tardi P G; Mayer L D; Bally M B
A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles.
Drug safety : an international journal of medical toxicology and drug experience 2001;24(12):903-20.
2000: Chi K C; Wallis A E; Lee C H; De Menezes D L; Sartor J; Dragowska W H; Mayer L D
Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression.
Breast cancer research and treatment 2000;63(3):199-212.
2000: Dragowska W H; Lopes de Menezes D E; Sartor J; Mayer L D
Quantitative fluorescence cytometric analysis of Bcl-2 levels in tumor cells exhibiting a wide range of inherent Bcl-2 protein expression: correlation with Western blot analysis.
Cytometry 2000;40(4):346-52.
2000: Lopes de Menezes D E; Hudon N; McIntosh N; Mayer L D
Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2891-902.
2000: Newman M J; Rodarte J C; Benbatoul K D; Romano S J; Zhang C; Krane S; Moran E J; Uyeda R T; Dixon R; Guns E S; Mayer L D
Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Cancer research 2000;60(11):2964-72.
2000: Johnstone S A; Gelmon K; Mayer L D; Hancock R E; Bally M B
In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines.
Anti-cancer drug design 2000;15(2):151-60.
1999: Krishna R; McIntosh N; Riggs K W; Mayer L D
Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10):2939-47.
1999: Krishna R; Mayer L D
The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
Anticancer research 1999;19(4B):2885-91.
1999: Gelmon K A; Tolcher A; Diab A R; Bally M B; Embree L; Hudon N; Dedhar C; Ayers D; Eisen A; Melosky B; Burge C; Logan P; Mayer L D
Phase I study of liposomal vincristine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(2):697-705.
1999: Mayer L D; Reamer J; Bally M B
Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation.
Journal of pharmaceutical sciences 1999;88(1):96-102.
1998: Webb M S; Saxon D; Wong F M; Lim H J; Wang Z; Bally M B; Choi L S; Cullis P R; Mayer L D
Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine.
Biochimica et biophysica acta 1998;1372(2):272-82.
1998: Mayer L D
Future developments in the selectivity of anticancer agents: drug delivery and molecular target strategies.
Cancer metastasis reviews 1998;17(2):211-8.
1998: Webb M S; Logan P; Kanter P M; St-Onge G; Gelmon K; Harasym T; Mayer L D; Bally M B
Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer.
Cancer chemotherapy and pharmacology 1998;42(6):461-70.
1998: Embree L; Gelmon K; Tolcher A; Hudon N; Heggie J; Dedhar C; Logan P; Bally M B; Mayer L D
Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection.
Cancer chemotherapy and pharmacology 1998;41(5):347-52.
1997: Embree L; Gelmon K A; Tolcher A W; Hudon N J; Heggie J R; Dedhar C; Webb M S; Bally M B; Mayer L D
Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection.
Journal of pharmaceutical and biomedical analysis 1997;16(4):675-87.
1997: Krishna R; Mayer L D
Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Cancer research 1997;57(23):5246-53.
1997: Krishna R; de Jong G; Mayer L D
Pulsed exposure of SDZ PSC 833 to multidrug resistant P388/ADR and MCF7/ADR cells in the absence of anticancer drugs can fully restore sensitivity to doxorubicin.
Anticancer research 1997;17(5A):3329-34.
1997: Cullis P R; Hope M J; Bally M B; Madden T D; Mayer L D; Fenske D B
Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles.
Biochimica et biophysica acta 1997;1331(2):187-211.
1997: Mayer L D; Dougherty G; Harasym T O; Bally M B
The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors.
The Journal of pharmacology and experimental therapeutics 1997;280(3):1406-14.
1995: Mayer L D; St-Onge G
Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques.
Analytical biochemistry 1995;232(2):149-57.
1995: Webb M S; Harasym T O; Masin D; Bally M B; Mayer L D
Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models.
British journal of cancer 1995;72(4):896-904.
1995: Webb M S; Wheeler J J; Bally M B; Mayer L D
The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery.
Biochimica et biophysica acta 1995;1238(2):147-55.
1995: Mayer L D; Masin D; Nayar R; Boman N L; Bally M B
Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours.
British journal of cancer 1995;71(3):482-8.
1994: Boman N L; Masin D; Mayer L D; Cullis P R; Bally M B
Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors.
Cancer research 1994;54(11):2830-3.
1994: Bally M B; Masin D; Nayar R; Cullis P R; Mayer L D
Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice.
Cancer chemotherapy and pharmacology 1994;34(2):137-46.
1993: Boman N L; Mayer L D; Cullis P R
Optimization of the retention properties of vincristine in liposomal systems.
Biochimica et biophysica acta 1993;1152(2):253-8.
1993: Embree L; Gelmon K A; Lohr A; Mayer L D; Coldman A J; Cullis P R; Palaitis W; Pilkiewicz F; Hudon N J; Heggie J R
Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients.
Journal of pharmaceutical sciences 1993;82(6):627-34.
1993: Mayer L D; Nayar R; Thies R L; Boman N L; Cullis P R; Bally M B
Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia.
Cancer chemotherapy and pharmacology 1993;33(1):17-24.
1991: Cullis P R; Bally M B; Madden T D; Mayer L D; Hope M J
pH gradients and membrane transport in liposomal systems.
Trends in biotechnology 1991;9(8):268-72.
1990: Mayer L D; Bally M B; Cullis P R; Wilson S L; Emerman J T
Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor.
Cancer letters 1990;53(2-3):183-90.
1990: Thies R L; Cowens D W; Cullis P R; Bally M B; Mayer L D
Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma.
Analytical biochemistry 1990;188(1):65-71.
1990: Mayer L D; Tai L C; Bally M B; Mitilenes G N; Ginsberg R S; Cullis P R
Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients.
Biochimica et biophysica acta 1990;1025(2):143-51.
1990: Bally M B; Nayar R; Masin D; Hope M J; Cullis P R; Mayer L D
Liposomes with entrapped doxorubicin exhibit extended blood residence times.
Biochimica et biophysica acta 1990;1023(1):133-9.
1990: Madden T D; Harrigan P R; Tai L C; Bally M B; Mayer L D; Redelmeier T E; Loughrey H C; Tilcock C P; Reinish L W; Cullis P R
The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey.
Chemistry and physics of lipids 1990;53(1):37-46.
1990: Mayer L D; Bally M B; Loughrey H; Masin D; Cullis P R
Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors.
Cancer research 1990;50(3):575-9.
1990: Bally M B; Nayar R; Masin D; Cullis P R; Mayer L D
Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes.
Cancer chemotherapy and pharmacology 1990;27(1):13-9.
1989: Mayer L D; Tai L C; Ko D S; Masin D; Ginsberg R S; Cullis P R; Bally M B
Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.
Cancer research 1989;49(21):5922-30.
1989: Redelmeier T E; Mayer L D; Wong K F; Bally M B; Cullis P R
Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients.
Biophysical journal 1989;56(2):385-93.
1989: Balazsovits J A; Mayer L D; Bally M B; Cullis P R; McDonell M; Ginsberg R S; Falk R E
Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin.
Cancer chemotherapy and pharmacology 1989;23(2):81-6.
1988: Janoff A S; Kurtz C L; Jablonski R L; Minchey S R; Boni L T; Gruner S M; Cullis P R; Mayer L D; Hope M J
Characterization of cholesterol hemisuccinate and alpha-tocopherol hemisuccinate vesicles.
Biochimica et biophysica acta 1988;941(2):165-75.
1988: Bally M B; Mayer L D; Loughrey H; Redelmeier T; Madden T D; Wong K; Harrigan P R; Hope M J; Cullis P R
Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients.
Chemistry and physics of lipids 1988;47(2):97-107.
1988: Mayer L D; Wong K F; Menon K; Chong C; Harrigan P R; Cullis P R
Influence of ion gradients on the transbilayer distribution of dibucaine in large unilamellar vesicles.
Biochemistry 1988;27(6):2053-60.
1987: Wong K F; Parmar Y I; Mayer L D; Pritchard P H; Cullis P R
Detection of protein-free lipoprotein analogues with an apolar lipid core by freeze-etch electron microscopy.
Biochimica et biophysica acta 1987;921(2):411-4.
1986: Mayer L D; Bally M B; Hope M J; Cullis P R
Techniques for encapsulating bioactive agents into liposomes.
Chemistry and physics of lipids 1986;40(2-4):333-45.
1986: Mayer L D; Hope M J; Cullis P R
Vesicles of variable sizes produced by a rapid extrusion procedure.
Biochimica et biophysica acta 1986;858(1):161-8.
1986: Mayer L D; Bally M B; Cullis P R
Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient.
Biochimica et biophysica acta 1986;857(1):123-6.
1986: Richards R L; Habbersett R C; Scher I; Janoff A S; Schieren H P; Mayer L D; Cullis P R; Alving C R
Influence of vesicle size on complement-dependent immune damage to liposomes.
Biochimica et biophysica acta 1986;855(2):223-30.
1985: Mayer L D; Hope M J; Cullis P R; Janoff A S
Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles.
Biochimica et biophysica acta 1985;817(1):193-6.
1985: Mayer L D; Bally M B; Hope M J; Cullis P R
Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential.
Biochimica et biophysica acta 1985;816(2):294-302.
1985: Mayer L D; Bally M B; Hope M J; Cullis P R
Uptake of dibucaine into large unilamellar vesicles in response to a membrane potential.
The Journal of biological chemistry 1985;260(2):802-8.
1984: Nayar R; Mayer L D; Hope M J; Cullis P R
Phosphatidic acid as a calcium ionophore in large unilamellar vesicle systems.
Biochimica et biophysica acta 1984;777(2):343-6.

Sign-in to see more